Sutro Biopharma
STRO
64 hedge funds and large institutions have $128M invested in Sutro Biopharma in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 6 closing their positions.
189% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 9
99% more capital inflows, than outflows
Capital inflows: $12.7M | Capital outflows: $6.41M
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
8% more funds holding
Funds holding: 59 → 64 (+5)
2.01% more ownership
Funds ownership: 48.3% → 50.31% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
+$7.42M |
| 2 |
OrbiMed
New York
|
+$1.08M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.03M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$356K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.84M |
| 2 |
Jennison Associates
New York
|
-$1.31M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$659K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$163K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$106K |
STRO Hedge Fund Activity: Q4 2019 in Review
64 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2019, worth a combined $128M — up 27% from $101M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new STRO positions and 6 closed out — a net gain of 5 holders — while 26 added to existing stakes and 9 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $7.42M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.84M sold.
- 64 institutional investors held Sutro Biopharma (STRO) as of Q4 2019, up from 59 in Q3 2019.
- Funds reported $128M of Sutro Biopharma stock for Q4 2019, up 27% quarter-over-quarter.
- 11 funds opened new Sutro Biopharma positions in Q4 2019 and 6 closed out, a net change of +5 holders.
- The largest Sutro Biopharma buyer in Q4 2019 was Eventide Asset Management, an estimated $7.42M added.
- The largest Sutro Biopharma seller in Q4 2019 was Sphera Funds Management, an estimated $3.84M sold.
Based on aggregated 13F filings for Q4 2019.